Design Therapeutics, Inc. financial data

Symbol
DSGN on Nasdaq
Location
6005 Hidden Valley Road, Suite 110, Carlsbad, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.49K % -29.7%
Debt-to-equity 4.7 % +28.8%
Return On Equity -30.6 % -69.7%
Return On Assets -29.2 % -68%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57M shares +0.61%
Common Stock, Shares, Outstanding 57M shares +0.61%
Entity Public Float 113M USD -31.2%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 57M shares +0.58%
Weighted Average Number of Shares Outstanding, Diluted 57M shares +0.58%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 57.9M USD +33.9%
General and Administrative Expense 20.1M USD +14.3%
Operating Income (Loss) -78M USD -28.3%
Net Income (Loss) Attributable to Parent -67.4M USD -41.2%
Earnings Per Share, Basic -1 USD/shares -41.7%
Earnings Per Share, Diluted -1 USD/shares -41.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.1M USD -50.3%
Marketable Securities, Current 191M USD -14.7%
Cash, Cash Equivalents, and Short-term Investments 206M USD -18.9%
Assets, Current 209M USD -18.7%
Property, Plant and Equipment, Net 1.1M USD -29.2%
Operating Lease, Right-of-Use Asset 1.64M USD -31.8%
Assets 212M USD -19.1%
Accounts Payable, Current 1.91M USD +30.1%
Employee-related Liabilities, Current 3.47M USD +16%
Accrued Liabilities, Current 9.26M USD +55.3%
Liabilities, Current 11.2M USD +50.3%
Operating Lease, Liability, Noncurrent 877K USD -49.7%
Liabilities 12.1M USD +31.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 358K USD -60.8%
Retained Earnings (Accumulated Deficit) -281M USD -31.6%
Stockholders' Equity Attributable to Parent 200M USD -20.9%
Liabilities and Equity 212M USD -19.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.8M USD -35%
Net Cash Provided by (Used in) Financing Activities 23K USD +15%
Net Cash Provided by (Used in) Investing Activities 7.87M USD -61.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 57M shares +0.61%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.9M USD -209%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.1M USD -50.3%
Deferred Tax Assets, Valuation Allowance 53.1M USD +25.2%
Deferred Tax Assets, Gross 54M USD +24.3%
Operating Lease, Liability 1.74M USD -30.9%
Depreciation 159K USD +11.2%
Payments to Acquire Property, Plant, and Equipment 72K USD -63.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68M USD -49.2%
Lessee, Operating Lease, Liability, to be Paid 1.88M USD -33.3%
Property, Plant and Equipment, Gross 3.21M USD +4.8%
Operating Lease, Liability, Current 866K USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 663K USD -31.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 973K USD +2.96%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 133K USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 663K USD -31.9%
Deferred Tax Assets, Operating Loss Carryforwards 18.9M USD +25.3%
Unrecognized Tax Benefits 2.29M USD +27.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 663K USD -31.9%
Deferred Tax Assets, Net of Valuation Allowance 836K USD -14.3%
Share-based Payment Arrangement, Expense 14.6M USD +18.3%